Menu
Advanced
Structure search
List search
EN
CN
ES
FR
JP
KR
Wish Lists
Cart
Sign in
Sign in
Contact us
Catalog
of Screening Compounds
Screening Libraries
Building Blocks
Advanced
Structure search
List search
Homepage
>
Company
>
Media
>
Pharma News
>
2019
Pharma News, 2019
Gilead Announces Data Demonstrating Non-Inferiority of Once-Daily Descovy® vs. Once-Daily Truvada® for Prevention of HIV Infection
FOSTER CITY, Calif.
Clinical trials of Allergan’s antidepressant rapastinel fail
An analyst said the news could negatively affect shares of a successor to the company that developed rapastinel - which Allergan bought in 2015 - given that its drugs belong to the same class.
Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update
WALTHAM, Mass.
Amgen Announces 2019 Second Quarter Dividend
THOUSAND OAKS, Calif.
Ozempic® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors
PLAINSBORO, N.
Alnylam Reports Positive Topline Results from ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria
CAMBRIDGE, Mass.
Protein inhibitor may help cure liver cancer: report
BEIJING, March 4 (Xinhua) -- Chinese scientists have identified a protein that causes the proliferation of liver cancer cells, a finding which could assist in the development of a new cancer d...
Ten years after the ‘Berlin patient,’ doctors announce a second person has been effectively ‘cured’ of HIV
For the second time, doctors appear to have put HIV into “sustained remission” with a stem cell transplant — effectively curing the recipient.
‘Wired into the walls’: Voice-recognition system promises to automate data entry during office visits
Hands down, the one task doctors complain about most is filling out the electronic health record during and after patient visits.
FDA approves esketamine, the first major depression treatment to reach U.S. market in decades
The Food and Drug Administration on Tuesday approved esketamine, the first major depression treatment to hit the U.
Biogen strikes $877M Nightstar gene therapy buyout
Biogen is set to pay $877 million (€772 million) to buy Nightstar Therapeutics for its pipeline of gene therapies.
BREAKING: FDA chief Scott Gottlieb steps down, leaving pet projects behind
In the past, AstraZeneca's investors have hit out at the company for executive compensation they deemed over-the-top.
46
47
48
49
50
51
52
53
54
0
item
s
in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Preplated libraries
Inhibitors and Approved Drugs
Screening Compounds
Building blocks
Inhibitors and approved drugs
Drug Discovery Services
Custom chemistry. Chemistry FTE. Resynthesis.
Hit Follow up Support
Medicinal chemistry FTE
In silico drug design (CADD)
Discovery Biology. Biology FTE. In vitro studies.
Animal models
Toxicology and safety
ADME, DMPK. In vivo studies
Chemistry, manufacturing and controls
Company
News & Media
Contact us
Trends in discovery compounds
